Trial Profile

A phase I/II trial assessing PA-001 to evaluate the safety, tolerability, and pharmacokinetics of PA001 in volunteers

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 14 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PA 001 (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; Proof of concept; Therapeutic Use

Most Recent Events

14 Aug 2023 According to PeptiAID media release, this trial having been adopted by the Japan Agency for Medical Research and Development (AMED) as apart of ''Research Program to Promote the Development of Innovative Therapeutics for Emerging and Re-emerging Infectious Diseases'' and will receive funding support from AMED to conduct clinical development activities.
14 Aug 2023 According to PeptiAID media release, company is preparing to file an IND application to the U.S. FDA and planning to start a Phase 1 clinical trial of PA-001 by the early/first quarter of 2024.
14 Oct 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com